Multidrug-resistant Pseudomonas aeruginosa infection in cystic fibrosis

Pseudomonas aeruginosa infection in cystic fibrosis (CF) is common and is associated with significant morbidity and mortality. Antibiotics aimed at Pseudomonas are used to eradicate early infection, suppress chronic infection, and treat acute exacerbations. Treatment options are limited due to increasing resistance and in vitro susceptibility information does not always correlate with in vivo outcomes. A case is presented with chronic Pseudomonas infection and the management and antibiotic choices for the patient during an acute hospital admission discussed, including the role of inhaled antibiotics such as tobramycin.